Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427918 | 0.91 | TYMP (0.43) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427963 | 0.84 | TYMP (0.43) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427908 | 0.84 | TYMP (0.44) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL941529 | 0.82 | LMNA (0.46) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427881 | 0.82 | TYMP (0.43) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL943184 | 0.82 | TYMP (0.43) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427919 | 0.81 | TYMP (0.42) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL14043101 | 0.78 | TYMP (0.44) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427867 | 0.77 | TYMP (0.41) | TYMPCA12CA1CA2CA9 | |
| SCHEMBL12427959 | 0.77 | TYMP (0.41) | TYMPCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | TYMP 781/4885CA12 453/4885CA1 128/4885 |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | TYMP 797/4885CA12 414/4885CA1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.